By 2032, the market for process monitoring is expected to increase from $5.51 billion to $13.3 billion.
With regulators boosting expectations for in-process controls, real-time monitoring, and lifecycle verification, and biopharma organizations investing in PAT, manufacturing intelligence, and sophisticated analytics, process monitoring has emerged as a crucial strategic priority.
Simultaneously, burgeoning biologics pipelines and enhanced modalities add complication. Global production networks put additional pressure on teams to enhance yield, ensure consistency, and improve operational efficiency while minimizing risk. In today’s environment, the problem is no longer gathering data, but rather transforming it into faster, more confident, and more effective choices across the product lifecycle.
The 5th Process Monitoring in Pharma Manufacturing Summit (previously the PAT & Real Time Quality Summit) brings together industry experts to transform aspiration into action.
Designed for pharma, biotech, and CDMO teams responsible for process performance, the meeting focuses on transitioning from fragmented technologies to integrated, end-to-end monitoring methods that generate meaningful business impact. Discover how successful companies are integrating real-time data into predictive insight, allowing for faster decision-making, lowering batch risk, and increasing yield and efficiency.
Join 60+ worldwide experts who share a goal: to establish process monitoring as a key driver of manufacturing excellence and competitive advantage.
Explore the full event guide
- Real-world case studies and lessons gained provide practical insights into how successful firms utilize process monitoring.
- Quickly discover the most relevant sessions and speakers across key emphasis areas, such as PAT, MSAT, technology transfer, quality, and analytics.
- Plan time effectively by prioritizing sessions that fit with your main concerns and business goals.
- Provide your team with a clear view of the agenda to help internal alignment and planning.
- Find specialized networking opportunities to compare approaches and engage with industry peers.
About 5th Process Monitoring in Pharma Manufacturing Summit
The process monitoring market is set to grow from $5.51 billion to $13.30 billion by 2032.
With regulators raising expectations around in-process controls, real-time monitoring, and lifecycle verification, and biopharma organizations increasing investment in PAT, manufacturing intelligence, and advanced analytics; process monitoring has become a critical strategic priority. At the same time, expanding biologics pipelines and advanced modalities are increasing complexity. Global manufacturing networks are placing additional pressure on teams to maximize yield, ensure consistency, and improve operational efficiency without increasing risk. In today’s environment, the challenge is no longer collecting data, but turning it into faster, more confident and impactful decisions across the product lifecycle.
The 5th Process Monitoring in Pharma Manufacturing Summit (formerly the PAT & Real Time Quality Summit) is where industry leaders come to turn ambition into execution. Designed for pharma, biotech, and CDMO teams driving process performance, the meeting focuses on shifting from fragmented tools to integrated, end-to-end monitoring strategies that deliver real business impact. Discover how leading organizations are transforming real-time data into predictive insight, enabling faster decision-making, reducing batch risk, and unlocking higher yield and efficiency.
Join 60+ global experts united by a common goal: positioning process monitoring as a core driver of manufacturing excellence and competitive advantage.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.